Patents by Inventor Françoise Baleux

Françoise Baleux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens
    Publication number: 20260115268
    Abstract: The present invention relates to mutants of an E. coli heat-stable toxin (ST) having the following wild-type sequence: NSSNYCCELCCNPACTGCY wherein the mutant has two mutations wherein the first mutation is selected from L9K, L9N and L9T and the second mutation is Al4T.
    Type: Application
    Filed: December 17, 2025
    Publication date: April 30, 2026
    Inventors: Pål Puntervoll, Françoise Baleux, Yves-Marie Coïc, Yuleima Diaz, Morten Andreas Govasli Larsen, Laurence Mulard, Arne Taxt, Ephrem Debebe Zegeye, Sandhya Srikant Visweswariah, Vishwas Mishra, Anaxee Barman
  • Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens
    Patent number: 12527853
    Abstract: The present invention relates to mutants of an E. coli heat-stable toxin (ST) having the following wild-type sequence: NSSNYCCELCCNPACTGCY wherein the mutant has two mutations wherein the first mutation is selected from L9K, L9N and L9T and the second mutation is A14T.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: January 20, 2026
    Assignee: VESTLANDETS INNOVASJONSSELSKAP AS (VIS)
    Inventors: Pål Puntervoll, Françoise Baleux, Yves-Marie Coïc, Yuleima Diaz, Morten Andreas Govasli Larsen, Laurence Mulard, Arne Taxt, Ephrem Debebe Zegeye, Sandhya Srikant Visweswariah, Vishwas Mishra, Anaxee Barman
  • Stapled peptide inhibitors of nemo as potential anti-inflammatory and anti-cancer drugs
    Patent number: 11884708
    Abstract: The invention concerns stapled peptide inhibitors of NEMO which inhibit the Nuclear Factor ?B (NF-?B) signaling pathway and are useful as medicine candidates, in particular as anti-inflammatory or anticancer drugs.
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: January 30, 2024
    Assignee: INSTITUT PASTEUR
    Inventors: Fabrice Agou, Alix Boucharlat, Yves-Marie Coic, Françoise Baleux
  • Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens
    Publication number: 20220249644
    Abstract: The present invention relates to mutants of an E. coli heat-stable toxin (ST) having the following wild-type sequence: NSSNYCCELCCNPACTGCY wherein the mutant has two mutations wherein the first mutation is selected from L9K, L9N and L9T and the second mutation is A14T.
    Type: Application
    Filed: August 22, 2019
    Publication date: August 11, 2022
    Inventors: Pål Puntervoll, Françoise Baleux, Yves-Marie Coïc, Yuleima Diaz, Morten Andreas Govasli Larsen, Laurence Mulard, Arne Taxt, Ephrem Debebe Zegeye, Sandhya Srikant Visweswariah, Vishwas Mishra, Anaxee Barman
  • STAPLED PEPTIDE INHIBITORS OF NEMO AS POTENTIAL ANTI-INFLAMMATORY AND ANTI-CANCER DRUGS
    Publication number: 20220025002
    Abstract: The invention concerns stapled peptide inhibitors of NEMO which inhibit the Nuclear Factor ?B (NF-?B) signaling pathway and are useful as medicine candidates, in particular as anti-inflammatory or anticancer drugs.
    Type: Application
    Filed: September 28, 2021
    Publication date: January 27, 2022
    Applicant: INSTITUT PASTEUR
    Inventors: Fabrice AGOU, Alix BOUCHARLAT, Yves-Marie COIC, Françoise BALEUX
  • Stapled peptide inhibitors of NEMO as potential anti-inflammatory and anti-cancer drugs
    Patent number: 11149070
    Abstract: The invention concerns stapled peptide inhibitors of NEMO which inhibit the Nuclear Factor ?B (NF-?B) signaling pathway and are useful as medicine candidates, in particular as anti-inflammatory or anticancer drugs.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: October 19, 2021
    Assignee: INSTITUT PASTEUR
    Inventors: Fabrice Agou, Alix Boucharlat, Yves-Marie Coic, Françoise Baleux
  • STAPLED PEPTIDE INHIBITORS OF NEMO AS POTENTIAL ANTI-INFLAMMATORY AND ANTI-CANCER DRUGS
    Publication number: 20190382456
    Abstract: The invention concerns stapled peptide inhibitors of NEMO which inhibit the Nuclear Factor ?B (NF-?B) signaling pathway and are useful as medicine candidates, in particular as anti-inflammatory or anticancer drugs.
    Type: Application
    Filed: December 22, 2016
    Publication date: December 19, 2019
    Inventors: Fabrice AGOU, Alix BOUCHARLAT, Yves-Marie COIC, Françoise BALEUX
  • Glycoconjugates and their use as potential vaccines against infection by
    Patent number: 9446109
    Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: September 20, 2016
    Assignee: INSERM (Institut National De La Sante Et De La Recherche Medicale)
    Inventors: Armelle Phalipon, Farida Nato, Laurence Mulard, Philippe Sansonetti, Françoise Baleux, Frédéric Belot, Cyrille Grandjean
  • Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanion for the treatment of AIDS
    Patent number: 9295730
    Abstract: This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: March 29, 2016
    Assignees: Institut Pasteur, Commissariat A L'Energie Atomique Et Aux Eneergies Alternatives, Centre National De La Recherche Scientifique (CNRS)
    Inventors: Françoise Baleux, David Bonnaffe, Hugues Lortat-Jacob, Latino Loureiro-Morais
  • Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanionic polypeptide for the treatment of AIDS
    Patent number: 9078928
    Abstract: This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Said organic molecule comprises a 5 to 21 amino acid anionic polypeptide. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: July 14, 2015
    Assignee: Institut Pasteur
    Inventors: Françoise Baleux, Hugues Lortat-Jacob, David Bonnaffe
  • NEW CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANIONIC POLYPEPTIDE FOR THE TREATMENT OF AIDS
    Publication number: 20140107043
    Abstract: This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Said organic molecule comprises a 5 to 21 amino acid anionic polypeptide. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS.
    Type: Application
    Filed: March 16, 2012
    Publication date: April 17, 2014
    Inventors: Françoise Baleux, Hugues Lortat-Jacob, David Bonnaffe
  • GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI
    Publication number: 20130243751
    Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
    Type: Application
    Filed: December 14, 2011
    Publication date: September 19, 2013
    Inventors: Armelle PHALIPON, Farida Nato, Laurence Mulard, Philippe Sansonetti, Françoise Baleux, Frédéric Belot, Cyrille Grandjean
  • Glycoconjugates and their use as potential vaccines against infection by
    Patent number: 8124380
    Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
    Type: Grant
    Filed: July 2, 2004
    Date of Patent: February 28, 2012
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Armelle Phalipon, Farida Nato, Laurence Mulard, Philippe Sansonetti, Françoise Baleux, Frédéric Belot, Cyrille Grandjean
  • CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS
    Publication number: 20110105412
    Abstract: This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS.
    Type: Application
    Filed: January 27, 2009
    Publication date: May 5, 2011
    Inventors: Françoise Baleux, David Bonnaffe, Hugues Lortat-Jacob, Latino Loureiro-Morais
  • CD4-RECEPTOR-DERIVED PEPTIDES AND METHOD FOR THE PREPARATION THEREOF
    Publication number: 20110015368
    Abstract: The present invention relates to an activated peptide derived from the CD4 receptor, which is capable of coupling by covalent bonding to an organic molecule and thus makes it possible to generate multiple potentially antiviral derivatives. The present invention also relates to a conjugated molecule comprising the CD4-receptor-derived peptide and an organic molecule, preferably the GPR1 peptide or a polyanion. Such a conjugated molecule can in particular be used in antiviral treatments, in particular the treatment of AIDS. The invention also relates to the methods for preparing the activated peptide derived from the CD4 receptor and the conjugated molecule.
    Type: Application
    Filed: August 3, 2007
    Publication date: January 20, 2011
    Inventors: Françoise Baleux, David Bonnaffe, Hugues Lortat-Jacob
  • Immunogenic glycopeptides, screening, preparation and uses
    Patent number: 7820142
    Abstract: The invention relates to immunogenic glycopeptides derived from pathogenic microorganisms, which can be used for immunization and diagnosing infections dye to such pathogenic microorganisms and also to method for the selection and preparation thereof.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: October 26, 2010
    Assignee: Institut Pasteur
    Inventors: Gilles Marchal, Félix Romain, Pascale Pescher, Françoise Baleux, Daniel Scott-Algara, Laurence Mulard